Overview

This white paper examines why pharmaceutical and life sciences manufacturers operating under 21 CFR Part 11 should adopt a two-database architecture that separates production SCADA databases from reporting databases. It argues that combining reporting and production workloads on a single system creates regulatory risk, performance degradation, and validation burden — all of which a well-designed two-database architecture avoids.

Key Topics Covered

• Why reporting workloads should be isolated from production SCADA databases
• Regulatory context: 21 CFR Part 11 controls, ALCOA+ data integrity principles
• Single-database vs. two-database architecture comparison
• The no-code and configuration argument for reducing validation burden
• Statistical and industry evidence from pharmaceutical manufacturing
• Performance, supportability, and change control benefits
• What a good implementation looks like: synchronization, schema design, access control

Industry Data Points

• 63% of pharma manufacturers experience unplanned downtime from critical asset issues
• 80% of FDA warning letters (2015–2016) included a data integrity component
• 40%+ of manufacturers experience production disruptions on a weekly or daily basis

Who This White Paper Is For

• Quality & Validation Leads — defending reporting architecture during inspection
• OT & Automation Engineers — maintaining SCADA and historian infrastructure
• IT & Data Architects — planning analytics layers over regulated production systems
• Plant IT & Digitalization Managers — weighing short-term convenience against long-term supportability